Genelux Corporation Announces New Chief Financial Officer
Genelux (NASDAQ: GNLX) has appointed Matthew Pulisic as its new Chief Financial Officer, effective January 30, 2025. Pulisic brings over 19 years of finance and commercial experience in the biopharmaceutical industry, having worked across the United States, Europe, and Asia.
Prior to joining Genelux, Pulisic served as Vice President of Finance at Arrowhead Pharmaceuticals, where he led planning and analysis and established a commercial manufacturing facility. He previously worked at Amgen in various finance roles, including Finance Director of Amgen Worldwide and Head of Capital Finance.
As part of his appointment, Pulisic received an inducement award of stock options to purchase 275,000 shares at $3.95 per share, vesting over four years with 25% vesting after one year and the remainder monthly over 36 months.
Genelux (NASDAQ: GNLX) ha nominato Matthew Pulisic come nuovo Chief Financial Officer, con effetto dal 30 gennaio 2025. Pulisic porta con sé oltre 19 anni di esperienza nel settore finanziario e commerciale nell'industria biopharmaceutica, avendo lavorato in Stati Uniti, Europa e Asia.
Prima di entrare in Genelux, Pulisic ha ricoperto il ruolo di Vice Presidente della Finanza presso Arrowhead Pharmaceuticals, dove ha guidato la pianificazione e l'analisi, nonché istituito una struttura di produzione commerciale. In precedenza, ha lavorato presso Amgen in vari ruoli finanziari, tra cui Direttore Finanziario di Amgen Worldwide e Responsabile della Finanza dei Capitali.
In seguito alla sua nomina, Pulisic ha ricevuto un premio di indennità in forma di opzioni sulle azioni per acquistare 275.000 azioni a 3,95 dollari per azione, con un periodo di maturazione di quattro anni, con il 25% che matura dopo un anno e il restante mensilmente per 36 mesi.
Genelux (NASDAQ: GNLX) ha nombrado a Matthew Pulisic como su nuevo Director Financiero, con efecto a partir del 30 de enero de 2025. Pulisic aporta más de 19 años de experiencia en finanzas y comercio en la industria biofarmacéutica, habiendo trabajado en Estados Unidos, Europa y Asia.
Antes de unirse a Genelux, Pulisic se desempeñó como Vicepresidente de Finanzas en Arrowhead Pharmaceuticals, donde lideró la planificación y el análisis y estableció una instalación de fabricación comercial. Anteriormente, trabajó en Amgen en varios roles financieros, incluyendo Director Financiero de Amgen Worldwide y Jefe de Finanzas de Capital.
Como parte de su nombramiento, Pulisic recibió una recompensa de inducción en forma de opciones sobre acciones para comprar 275,000 acciones a $3.95 por acción, con un período de consolidación de cuatro años, con el 25% consolidándose después de un año y el resto mensualmente durante 36 meses.
Genelux (NASDAQ: GNLX)는 Matthew Pulisic을 새로운 최고재무책임자(CFO)로 임명하였으며, 이는 2025년 1월 30일부터 효력이 발생합니다. Pulisic은 생물제약 산업에서 19년 이상의 재무 및 상업 경험을 가지고 있으며, 미국, 유럽 및 아시아에서 일한 경력이 있습니다.
Genelux에 합류하기 전, Pulisic은 Arrowhead Pharmaceuticals의 재무 부사장으로 재직하며 계획 및 분석을 주도하고 상업 제조 시설을 설립하였습니다. 이전에는 Amgen에서 다양한 재무 직책을 맡으며 Amgen Worldwide의 재무 이사 및 자본 재무 책임자로 일했습니다.
임명됨에 따라 Pulisic은 275,000주를 주당 $3.95에 구매할 수 있는 주식 옵션 유인 보상 수여를 받았으며, 이는 4년 동안 분할 변동하며 첫 해가 지나면 25%가 검증되고 나머지는 36개월에 걸쳐 월별로 검증됩니다.
Genelux (NASDAQ: GNLX) a nommé Matthew Pulisic en tant que nouveau directeur financier, prenant effet le 30 janvier 2025. Pulisic apporte plus de 19 ans d'expérience en finance et commerce dans l'industrie biopharmaceutique, ayant travaillé aux États-Unis, en Europe et en Asie.
Avant de rejoindre Genelux, Pulisic était vice-président des finances chez Arrowhead Pharmaceuticals, où il a dirigé la planification et l'analyse et établi une installation de fabrication commerciale. Auparavant, il a travaillé chez Amgen dans divers rôles financiers, y compris directeur financier d'Amgen Worldwide et responsable des finances d'investissement.
Dans le cadre de sa nomination, Pulisic a reçu une récompense d'incitation sous forme d'options d'achat d'actions pour acquérir 275 000 actions à 3,95 dollars par action, cette récompense se consolidant sur quatre ans avec 25 % après un an et le reste mensuellement pendant 36 mois.
Genelux (NASDAQ: GNLX) hat Matthew Pulisic als neuen Chief Financial Officer ernannt, der am 30. Januar 2025 wirksam wird. Pulisic bringt über 19 Jahre Finanz- und Geschäftserfahrung in der biopharmazeutischen Industrie mit, nachdem er in den Vereinigten Staaten, Europa und Asien gearbeitet hat.
Vor seinem Eintritt bei Genelux war Pulisic Vizepräsident der Finanzen bei Arrowhead Pharmaceuticals, wo er die Planung und Analyse leitete und eine kommerzielle Fertigungsanlage einrichtete. Davor arbeitete er bei Amgen in verschiedenen Finanzpositionen, darunter Finanzdirektor von Amgen Worldwide und Leiter der Kapitalfinanzen.
Im Rahmen seiner Ernennung erhielt Pulisic einen Anreiz in Form von Aktienoptionen, um 275.000 Aktien zu einem Preis von 3,95 USD pro Aktie zu erwerben, die über vier Jahre laufen, wobei 25 % nach einem Jahr und der Rest monatlich über 36 Monate fällig wird.
- Appointment of experienced CFO with 19 years of finance and commercial experience in biotech
- New CFO has relevant experience in transitioning companies from clinical to commercial stage
- Strategic hire aligned with potential Olvi-Vec launch preparations
- Significant stock option grant (275,000 shares) represents potential future dilution for shareholders
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025.
"I am very pleased to welcome Matt as our new Chief Financial Officer. Matt’s financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux,” said Thomas Zindrick, President, CEO and Chairman of the Board. “His unique combination of financial expertise and scientific background will be valuable as the company continues building towards the potential launch of Olvi-Vec.”
Mr. Pulisic is an accomplished, senior executive with over 19 years of finance and commercial experience in the biopharmaceutical industry, having worked across the United States, Europe, and Asia. He is recognized for his expertise in financial leadership, corporate strategy and operational execution.
Most recently, Mr. Pulisic served as Vice President of Finance at Arrowhead Pharmaceuticals, a publicly traded RNAi technology company. He played a key role in shaping the company’s financial direction, leading planning and analysis, establishing a commercial manufacturing facility, and driving operational improvements to support the company’s evolution from a clinical-stage to a pre-commercial organization. He began his career at Amgen, a publicly traded commercial biotechnology company, as a Research Associate and transitioned into finance where he held positions of increasing responsibility, across a breadth of finance-related positions, including Finance Director of Amgen Worldwide and Head of Capital Finance. He graduated from California Lutheran University with his M.B.A. in finance and from the University of California, Santa Cruz with his B.S. in Biochemistry and Molecular Biology.
“I am excited to join the Genelux team and look forward to advancing our financial strategy, delivering enhanced shareholder value and bringing life-changing therapies to patients,” said Mr. Pulisic.
In connection with his appointment as Chief Financial Officer, Mr. Pulisic was granted an inducement award of a stock option to purchase 275,000 shares of common stock under the Company’s 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), at an exercise price of
About Genelux Corporation
Genelux is a late-stage clinical biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “believes,” “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to Mr. Pulisic’s expected contribution to the Company and the potential launch of Olvi-Vec. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified under the caption “Risk Factors” in Genelux’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Genelux does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d4325c77-1241-4a93-9957-42ea72fb6fe8
FAQ
Who is the new CFO of Genelux (GNLX) and when did they start?
What is the size and terms of the stock option grant given to GNLX's new CFO?
What is Matthew Pulisic's previous experience before joining GNLX?
How does the new CFO appointment align with GNLX's strategic goals?
